Tom Chittenden, DPhil, PhD, PStat is the Vice President of Data Sciences for the United Sigma Intelligence Association.
Dr. Chittenden is an Omega Society Fellow with over 25 years of experimental and theoretical research experience. Dr. Chittenden is an Accredited Professional Statistician™ with the American Statistical Association. He holds academic faculty appointments at Boston Children’s Hospital and the Harvard Medical School.
From 2016 to 2018, Dr. Chittenden held a Visiting Lecturer appointment in the Department of Biological Engineering at the Massachusetts Institute of Technology (MIT). Dr. Chittenden is the Chairman of the Scientific and Medical Advisory Board for Bio-AI Health. He is Senior Research Fellow and the Chief Statistical Sciences Advisor for the Global Strategic Initiatives and Planning Committee of the International Society for Philosophical Enquiry. He is also a Scientific Advisory Board member of BlueRock Therapeutics and the Alliance for Artificial Intelligence in Healthcare.
Dr. Chittenden is Chief Data Science Officer and Founding Director of the Genuity Science Advanced Artificial Intelligence Research Laboratory. Dr. Chittenden is responsible for development and execution of Genuity Science’s global AI/ML R&D strategy. This R&D initiative includes development of advance integrative deep learning, statistical machine learning, probabilistic programming, and structural causal modeling strategies aimed at furthering scientific understanding of human disease initiation and progression, knowledge that can be directly applied in innovative products for better care and medicine in a range of disease areas.
Dr. Chittenden is the Chairman, Founding President and Chief Scientist for the Complex Biological Systems Alliance (CBSA), a non-profit global research consortium dedicated to furthering scientific understanding of biological complexity and the nature and origins of human disease. In 2014, Dr. Chittenden established the CBSA as a recognized Extreme Science and Engineering Discovery Environment (XSEDE) Campus. Through the XSEDE Campus Champions Program, the Alliance provides its investigators with direct access to a national consortium of supercomputing facilities supported by the National Science Foundation.
Through a formal academic research collaboration with the USC-Lockheed Martin Quantum Computation Center, Dr. Chittenden’s Lab has access to quantum computing hardware. His team has recently developed novel quantum machine learning (qML) strategies, which provide competitive classification of human cancer types and associated molecular tumor subtypes and ‘superior’ performance with smaller patient training dataset sizes, thus providing compelling empirical evidence for the potential of this emerging field. Dr. Chittenden’s team is also investigating the utility of neuromorphic computing in the biomedical sciences. Their newly developed deep spiking neural networks indicate even greater potential than qML. Via a formal academic research collaboration with the Yale University School of Medicine, Dr. Chittenden and his colleagues are pioneering the field of single cell science.
Dr. Chittenden’s research has been published in top-tier scientific journals, including featured articles in Nature and Science. In 2019, Forbes named Dr. Chittenden among the top 100 A.I. Leaders in Drug Discovery and Advanced Healthcare. He is regarded as one of the world’s leading authorities on A.I. and causal statistical machine learning in precision medicine.
Dr. Chittenden holds a PhD in Molecular Cell Biology and Biotechnology from Virginia Tech and a DPhil in Computational Statistics from the University of Oxford. His multidisciplinary postdoctoral training includes experimental investigations in molecular and cellular cardiology from the Dartmouth Medical School; biostatistics and computational biology from the Dana‐Farber Cancer Institute and the Harvard School of Public Health; and computational statistics, statistical methodology and statistical machine learning from the University of Oxford.
He is a member of the Omega Society, one-in-a-million society.
Sientific Research Publications
Please find all of Dr. Tom Chittenden PhD DPhil scientific research publications. [Link]
Featured on cover of the October 2nd 2015 issue of Science.
A Neuroscience Perspective on the potential impact in medicine and biology.
Neurons live for decades in a postmitotic state, their genomes susceptible to DNA damage. Here we survey the landscape of somatic single-nucleotide variants (SNVs) in the human brain. We identified thousands of somatic SNVs by single-cell sequencing of 36 neurons from the cerebral cortex of three normal individuals. Unlike germline and cancer SNVs, which are often caused by errors in DNA replication, neuronal mutations appear to reflect damage during active transcription. Somatic mutations create nested lineage trees, allowing them to be dated relative to developmental landmarks and revealing a polyclonal architecture of the human cerebral cortex. Thus, somatic mutations in the brain represent a durable and ongoing record of neuronal life history, from development through postmitotic function.